Table 3.
SSP-reported impacts of COVID-19 on program operations, February-April 2021 (N=27).
| Operations compared to pre-COVID | Less than pre-COVID | About the same | More than pre-COVID | N/A |
|---|---|---|---|---|
| Hours of operation | 8 (30%) | 14 (52%) | 5 (19%) | 0 (0%) |
| Number of staff | 3 (11%) | 17 (63%) | 5 (19%) | 2 (7%) |
| Number of volunteers | 11 (41%) | 7 (26%) | 5 (19%) | 4 (15%) |
| Number of participants per week | 11 (41%) | 5 (19%) | 11 (41%) | 0 (0%) |
| Number of syringes distributed per week | 7 (26%) | 5 (19%) | 15 (56%) | 0 (0%) |
| Number of syringes per participant | 3 (11%) | 8 (30%) | 16 (59%) | 0 (0%) |
| Overall naloxone distribution | 4 (15%) | 3 (11%) | 20 (74%) | 0 (0%) |
| Home delivery | 1 (4%) | 3 (11%) | 13 (48%) | 10 (37%) |
| Any mobile delivery | 1 (4%) | 6 (22%) | 14 (52%) | 6 (2%) |
| HIV testing | 14 (52%) | 8 (30%) | 1 (4%) | 4 (15%) |
| HCV testing | 14 (52%) | 8 (30%) | 1 (4%) | 4 (15%) |
| Linkages to SUD treatment | 10 (37%) | 11 (41%) | 5 (19%) | 1 (4%) |
*Note: All estimates are row percentages.